Emergent Biosolutions (NYSE:EBS) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of Emergent Biosolutions (NYSE:EBS) to a hold rating in a research report report published on Tuesday morning,Zacks.com reports.

EBS has been the subject of a number of other reports. Benchmark restated a “buy” rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd. HC Wainwright dropped their target price on shares of Emergent Biosolutions from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Emergent Biosolutions in a report on Friday, August 7th. Finally, UBS Group reissued a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $10.00.

Emergent Biosolutions Trading Up 2.2%

NYSE EBS opened at $4.55 on Tuesday. Emergent Biosolutions has a 12 month low of $4.36 and a 12 month high of $14.06. The company has a current ratio of 5.42, a quick ratio of 2.95 and a debt-to-equity ratio of 1.70. The stock’s fifty day moving average price is $7.59 and its 200-day moving average price is $8.60. The stock has a market cap of $233.29 million, a P/E ratio of -1.28 and a beta of 2.35.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.68. The firm had revenue of $234.30 million during the quarter, compared to analyst estimates of $177.50 million. Emergent Biosolutions had a positive return on equity of 16.35% and a negative net margin of 22.95%. As a group, equities analysts forecast that Emergent Biosolutions will post -4.63 EPS for the current fiscal year.

Insider Activity

In other news, SVP Paul Anthony Williams sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total transaction of $25,200.00. Following the sale, the senior vice president owned 159,098 shares of the company’s stock, valued at $1,336,423.20. This trade represents a 1.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EBS. Pacer Advisors Inc. purchased a new position in Emergent Biosolutions in the first quarter worth about $3,454,000. Dimensional Fund Advisors LP increased its position in shares of Emergent Biosolutions by 22.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,757,158 shares of the biopharmaceutical company’s stock valued at $22,884,000 after purchasing an additional 504,553 shares during the last quarter. Evolve Private Wealth LLC bought a new position in shares of Emergent Biosolutions in the 1st quarter worth approximately $546,000. Renaissance Technologies LLC boosted its holdings in shares of Emergent Biosolutions by 13.7% in the first quarter. Renaissance Technologies LLC now owns 656,047 shares of the biopharmaceutical company’s stock worth $5,445,000 after buying an additional 78,900 shares during the last quarter. Finally, SG Americas Securities LLC boosted its holdings in shares of Emergent Biosolutions by 4.6% in the first quarter. SG Americas Securities LLC now owns 42,394 shares of the biopharmaceutical company’s stock worth $352,000 after buying an additional 1,865 shares during the last quarter. Institutional investors own 78.40% of the company’s stock.

Emergent Biosolutions News Summary

Here are the key news stories impacting Emergent Biosolutions this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $10 price target. The firm projects Emergent will return to profitability in 2027, forecasting fiscal 2027 EPS of $0.28 after an estimated fiscal 2026 loss of $4.63 per share. Longer-term earnings expectations provide a potential recovery catalyst if the company stabilizes operations. HC Wainwright forecast article
• Neutral Sentiment: Management’s Q2 2026 earnings call transcript is now available. Investors are likely examining the call for additional detail on the NARCAN franchise, competitive conditions, pricing, cost controls and the path toward the projected 2027 profitability. Emergent BioSolutions Q2 2026 earnings call transcript
• Negative Sentiment: Emergent disclosed a $191.3 million non-cash impairment charge against its NARCAN franchise. The write-down was attributed to increased competition and pricing pressure in the naloxone market, raising concerns about the franchise’s future revenue and profitability. Levi and Korsinsky investor investigation notice
• Negative Sentiment: A law firm announced an investor investigation following shareholder losses. Although the announcement does not establish wrongdoing, the investigation adds legal and reputational risk and may increase volatility.
• Negative Sentiment: Near-term earnings forecasts remain weak. HC Wainwright expects losses of $0.75 per share in Q3 2026 and $0.64 in Q4 2026, reinforcing concerns that the impairment and NARCAN market pressures will continue affecting results.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.